Cyclo(RGDyK) |
Catalog No.GC13923 |
Cyclo(RGDyK)는 IC50 값이 20 nM인 강력하고 선택적인 αVβ3 인테그린 억제제입니다.
Products are for research use only. Not for human use. We do not sell to patients.
Cas No.: 250612-42-1
Sample solution is provided at 25 µL, 10mM.
Quality Control & SDS
- View current batch:
- Purity: >99.50%
- COA (Certificate Of Analysis)
- SDS (Safety Data Sheet)
- Datasheet
Cell experiment [1]: | |
Cell lines |
B16-F10 cells and HUVEC |
Preparation Method |
Dil-loaded micellar formulations with different Cyclo(RGDyK) densities (0%, 10%, 20%) were incubated with B16-F10 cells or HUVEC in six-well plates for 3 h at 37°C at a final concentration of 0.5 ug/mL or 0.1 ug/mL Dil diluted in culture media, respectively. And the cells incubated with medium were used as negative controls. For the competition experiments, free Cyclo(RGDyK) (0.8 mM for B16-F10 and 1.6 µM for HUVEC) was pre-incubated with cells for 1 h, followed by continued co-incubation with Cyclo(RGDyK)-Dil-PM with 20% cRGDyK for 3 h. Then, cells were washed, trypsinized, and neutralized. After centrifugation at 1200 rpm for 5 min, cells were resuspended in PBS, followed by filtra |
Reaction Conditions |
0.8 mM for B16-F10 and 1.6 µM for HUVEC Cyclo(RGDyK) for 1 h |
Applications |
PEG-b-PLGA micelles without or with Cyclo(RGDyK) conjugation loaded with paclitaxel (PTX) or DiI were prepared and characterized. Drug-loaded micelles were stable in solution, with small diameters ( |
Animal experiment [2]: | |
Animal models |
C57BL/6 mice |
Preparation Method |
Forty 3-month old female C57BL/6 mic were randomly allocated into four groups: (1) Sham-operated (Sham); (2) ovariectomized; (3) Ovx plus 8-week downhill running exercise (Ex); (4) Ovx plus exercise and received twice weekly injection of Cyclo(RGDyK) protein (a putative anti-irisin receptor agents) (ExRg). |
Dosage form |
2.5 mg/kg Cyclo(RGDyK) twice a week(tail vein injection) |
Applications |
Cyclo(RGDyK) administration weakened the exercise-related improvement of vBMD, BV/TV, and ALP intensity in bone. |
References: [1]. Yin J, Li Z, et,al. Cyclic RGDyK conjugation facilitates intracellular drug delivery of polymeric micelles to integrin-overexpressing tumor cells and neovasculature. J Drug Target. 2011 Jan;19(1):25-36. doi: 10.3109/10611861003663531. Epub 2010 Mar 16. PMID: 20233083. |
Cyclo(RGDyK)는 IC50 값이 20 nM인 강력하고 선택적인 αVβ3 인테그린 억제제입니다. [1]
팔리탁셀(PTX) 또는 DiI로 로드된 Cyclo(RGDyK) 결합 여부가 없는 PEG-b-PLGA 마이셀을 제조하고 특성화했습니다. 약물이 로드된 마이셀은 용액에서 안정적이며 직경이 작습니다 ([5]).
화학적 결합을 통해 독소르빈과 펩타이드 Cyclo(RGDyK)를 합성된 이중 기능 자석 나노입자(DMP)에 부착하여, 자기 타겟팅, 인테그린 알파(v)베타3 타겟팅 및 고용량 약물 전달 기능을 결합한 새로운 약물 전달 시스템인 Cyclo(RGDyK)-수정 Fe3O4 나노입자 (R-DMP)가 개발되었다. D-DMP는 인테그린 알파(v)베타3을 발현하는 종양 세포에서 강화된 흡수를 보이며 더 강한 항암 세포 독성을 나타낸다[2].
Cyclo(RGDyK) 투여는 뼈의 vBMD, BV/TV 및 ALP 강도에 대한 운동 관련 개선을 약화시켰습니다[4]. Irisin 수용체 (αV/β5)를 차단함으로써 Cyclo(RGDyK)는 irisin 유도 신호를 감소시킬 수 있습니다. Irisin 경로가 차단될 때 일부 골모세포 생성 유전자가 감소되어 Cyclo(RGDyK)-유도 골형성 분화의 감소에 기여할 수 있습니다[3].
References:
[1]: Haubner R, Wester HJ, et,al. Glycosylated RGD-containing peptides: tracer for tumor targeting and angiogenesis imaging with improved biokinetics. J Nucl Med. 2001 Feb;42(2):326-36. PMID: 11216533.
[2]: Guo L, Ding W, et,al. The C(RgdyK)-conjugated Fe3O4 nanoparticles with high drug load for dual-targeting integrin alpha(v)beta3-expressing cancer cells. J Nanosci Nanotechnol. 2014 Jul;14(7):4858-64. doi: 10.1166/jnn.2014.8691. PMID: 24757954.
[3]: Kim H, Wrann CD, et,al. Irisin Mediates Effects on Bone and Fat via αV Integrin Receptors. Cell. 2018 Dec 13;175(7):1756-1768.e17. doi: 10.1016/j.cell.2018.10.025. Erratum in: Cell. 2019 Jul 11;178(2):507-508. PMID: 30550785; PMCID: PMC6298040.
[4]:Zhao R, Zhou Y, et,al. Irisin Regulating Skeletal Response to Endurance Exercise in Ovariectomized Mice by Promoting Akt/β-Catenin Pathway. Front Physiol. 2021 Mar 25;12:639066. doi: 10.3389/fphys.2021.639066. PMID: 33841178; PMCID: PMC8027323.
[5]:Yin J, Li Z, et,al. Cyclic RGDyK conjugation facilitates intracellular drug delivery of polymeric micelles to integrin-overexpressing tumor cells and neovasculature. J Drug Target. 2011 Jan;19(1):25-36. doi: 10.3109/10611861003663531. Epub 2010 Mar 16. PMID: 20233083.
Cas No. | 250612-42-1 | SDF | |
Chemical Name | 2,2,2-trifluoroacetic acid compound with 2-((1Z,2S,3Z,5R,6Z,8S,9Z,11S,12Z)-8-(4-aminobutyl)-11-(3-guanidinopropyl)-3,6,9,12,15-pentahydroxy-5-(4-hydroxybenzyl)-1,4,7,10,13-pentaazacyclopentadeca-3,6,9,12,15-pentaen-2-yl)acetic acid (2:1) | ||
Canonical SMILES | NCCCC[C@@]1([H])/C(O)=N/[C@@](/C(O)=N/C/C(O)=N/[C@@](/C(O)=N/[C@](/C(O)=N/1)([H])CC2=CC=C(O)C=C2)([H])CC(O)=O)([H])CCCNC(N)=N.FC(F)(F)C(O)=O.FC(F)(F)C(O)=O | ||
Formula | C31H43F6N9O12 | M.Wt | 847.72 |
Solubility | DMSO : 100mg/mL; Water : 100mg/mL | Storage | Store at -20°C |
General tips | Please select the appropriate solvent to prepare the stock solution according to the
solubility of the product in different solvents; once the solution is prepared, please store it in
separate packages to avoid product failure caused by repeated freezing and thawing.Storage method
and period of the stock solution: When stored at -80°C, please use it within 6 months; when stored
at -20°C, please use it within 1 month. To increase solubility, heat the tube to 37°C and then oscillate in an ultrasonic bath for some time. |
||
Shipping Condition | Evaluation sample solution: shipped with blue ice. All other sizes available: with RT, or with Blue Ice upon request. |
Prepare stock solution | |||
1 mg | 5 mg | 10 mg | |
1 mM | 1.1796 mL | 5.8982 mL | 11.7963 mL |
5 mM | 0.2359 mL | 1.1796 mL | 2.3593 mL |
10 mM | 0.118 mL | 0.5898 mL | 1.1796 mL |
Step 1: Enter information below (Recommended: An additional animal making an allowance for loss during the experiment)
Step 2: Enter the in vivo formulation (This is only the calculator, not formulation. Please contact us first if there is no in vivo formulation at the solubility Section.)
Calculation results:
Working concentration: mg/ml;
Method for preparing DMSO master liquid: mg drug pre-dissolved in μL DMSO ( Master liquid concentration mg/mL, Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug. )
Method for preparing in vivo formulation: Take μL DMSO master liquid, next addμL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O, mix and clarify.
Method for preparing in vivo formulation: Take μL DMSO master liquid, next add μL Corn oil, mix and clarify.
Note: 1. Please make sure the liquid is clear before adding the next solvent.
2. Be sure to add the solvent(s) in order. You must ensure that the solution obtained, in the previous addition, is a clear solution before proceeding to add the next solvent. Physical methods such as vortex, ultrasound or hot water bath can be used to aid dissolving.
3. All of the above co-solvents are available for purchase on the GlpBio website.
Average Rating: 5
(Based on Reviews and 22 reference(s) in Google Scholar.)GLPBIO products are for RESEARCH USE ONLY. Please make sure your review or question is research based.
Required fields are marked with *